Corline Biomedical Financials
| CLBIO Stock | SEK 9.48 0.10 1.04% |
Corline |
Understanding current and past Corline Biomedical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Corline Biomedical's financial statements are interrelated, with each one affecting the others. For example, an increase in Corline Biomedical's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Corline Biomedical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corline Biomedical AB. Check Corline Biomedical's Beneish M Score to see the likelihood of Corline Biomedical's management manipulating its earnings.
Corline Biomedical Stock Summary
Corline Biomedical competes with Bavarian Nordic, BioPorto, Zaptec AS, and CBrain AS. Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. The company was founded in 1991 and is based in Uppsala, Sweden. Corline Biomedical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 9 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0006887451 |
| Business Address | Lefflersgatan 5, Uppsala, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.corline.se |
| Phone | 46 18 71 30 90 |
| Currency | SEK - Swedish Kronor |
You should never invest in Corline Biomedical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Corline Stock, because this is throwing your money away. Analyzing the key information contained in Corline Biomedical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Corline Biomedical Key Financial Ratios
There are many critical financial ratios that Corline Biomedical's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Corline Biomedical reports annually and quarterly.| Return On Equity | 0.0075 | |||
| Return On Asset | 0.0044 | |||
| Target Price | 29.0 | |||
| Number Of Employees | 10 | |||
| Beta | 0.8 |
Corline Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Corline Biomedical's current stock value. Our valuation model uses many indicators to compare Corline Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Corline Biomedical competition to find correlations between indicators driving Corline Biomedical's intrinsic value. More Info.Corline Biomedical AB is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Corline Biomedical AB is roughly 1.70 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Corline Biomedical's earnings, one of the primary drivers of an investment's value.Corline Biomedical Systematic Risk
Corline Biomedical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Corline Biomedical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Corline Biomedical correlated with the market. If Beta is less than 0 Corline Biomedical generally moves in the opposite direction as compared to the market. If Corline Biomedical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Corline Biomedical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Corline Biomedical is generally in the same direction as the market. If Beta > 1 Corline Biomedical moves generally in the same direction as, but more than the movement of the benchmark.
Corline Biomedical Thematic Clasifications
Corline Biomedical AB is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
Corline Biomedical January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Corline Biomedical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Corline Biomedical AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Corline Biomedical AB based on widely used predictive technical indicators. In general, we focus on analyzing Corline Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Corline Biomedical's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.5 | |||
| Information Ratio | 0.0788 | |||
| Maximum Drawdown | 16.49 | |||
| Value At Risk | (4.81) | |||
| Potential Upside | 8.88 |
Additional Tools for Corline Stock Analysis
When running Corline Biomedical's price analysis, check to measure Corline Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corline Biomedical is operating at the current time. Most of Corline Biomedical's value examination focuses on studying past and present price action to predict the probability of Corline Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corline Biomedical's price. Additionally, you may evaluate how the addition of Corline Biomedical to your portfolios can decrease your overall portfolio volatility.